Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TGTX research report →
Range $78 – $83
Price Chart
About the company
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions.
- CEO
- Michael S. Weiss
- IPO
- 2010
- Employees
- 399
- HQ
- Morrisville, NY, US
Get TickerSpark's AI analysis on TGTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $9.48B
- P/E
- 84.19
- Fwd P/E
- 60.63
- PEG
- -1.11
- P/S
- 10.56
- P/B
- 15.43
- EV/EBITDA
- 51.24
- Div Yield
- 0.00%
- Gross Margin
- 82.74%
- Op Margin
- 21.48%
- Net Margin
- 11.81%
- ROE
- 17.62%
- ROIC
- 10.26%
Latest fiscal year · YoY change
- Revenue
- $616.29M+87.3%
- Gross Profit
- $515.57M+77.5%
- Op Income
- $123.32M
- Net Income
- $447.18M+1812.4%
- EPS
- $3.10+1837.5%
- OCF Growth
- +38.9%
- FCF Growth
- +38.4%
- Beta
- 1.81
- RSI (14)
- 62
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
TG Therapeutics delivered another strong quarter on BRIUMVI growth, raised 2026 revenue guidance, and highlighted progress toward future IV and subcutaneous launches.· November 9, 2026
- Q3 global revenue was about $260 million, including $233 million of U.S. BRIUMVI net revenue; U.S. BRIUMVI revenue was up 52% year over year and total revenue was up 61%.
- Management raised full-year 2026 guidance to about $1 billion in total global revenue and increased U.S. BRIUMVI net product revenue guidance to $915 million-$920 million.
- U.S. BRIUMVI gross margin was 87%, consolidated gross margin was about 84%, and net income was $55.5 million, or $0.35 per diluted share.
- Commercial momentum remained strong: new patient starts accelerated late in Q3 and into Q4, October was a record month for total prescribers, and hospital business had its strongest months since launch.
- Clinical updates reinforced the long-term story: seven-year BRIUMVI data showed sustained efficacy, the single-dose IV initiation met its endpoint, and subcutaneous BRIUMVI remained on track for potential launch in 2028.
TG reported Q3 2026 total revenue of approximately $260 million, up 61% year over year, including $233 million of U.S. BRIUMVI net revenue, up 52% year over year, plus $7.4 million from ex-U.S. product sales and $19.9 million of license, milestone, royalty and other revenue. U.S. BRIUMVI gross margin was 87% and consolidated gross margin was approximately 84%. Operating income was $86 million, and net income was $55.5 million, or $0.35 per diluted share. For full-year 2026, management raised total global revenue guidance to approximately $1 billion, raised U.S. BRIUMVI net product revenue guidance to $915 million-$920 million, and kept full-year R&D and SG&A guidance at $450 million-$500 million excluding stock-based compensation.
Mike Weiss framed the quarter as proof that BRIUMVI is becoming a much larger platform than an initial launch product. He emphasized the company’s ambition to become the most prescribed anti-CD20 therapy among new MS starts and pointed to two future growth drivers: a simplified single-initiation IV dose targeted for around mid-2027 and self-administered subcutaneous BRIUMVI targeted for 2028. His tone was upbeat and expansionary, with repeated emphasis that TG is still early in what it can become.
Sean Power said commercial performance stayed strong, with U.S. BRIUMVI revenue at $233 million and total revenue at about $260 million. He highlighted strong margins, including 87% U.S. gross margin and 84% consolidated gross margin, and said operating income reached $86 million. On capital allocation, the company ended September with about $557 million in cash equivalents and investment securities and repurchased $100 million of stock in Q3, bringing cumulative buybacks to $300 million, or about 8.9 million shares. He also said full-year R&D and SG&A, excluding stock comp, should remain in the prior $450 million-$500 million range.
Analysts focused on gross-to-net pressure, BTK inhibitor competition, 2027 growth timing, subcutaneous launch details, 340B exposure, and the pace of uptake for the simplified IV regimen and subcu BRIUMVI. Management said its contracting is competitive and sustainable, and that gross-to-net will face normal pressure over time but the company is managing net price and still raising revenue guidance. On BTK inhibitors, management argued the class looks more like a competitor in the oral space than in high-efficacy CD20 therapy, citing efficacy and safety limitations. They also said the simplified IV dose should help later in 2027 and into 2028, while 340B exposure appears limited at roughly 5% of business and may have minimal impact.
The call showed strong underlying demand, with sequential growth for 14 straight quarters and accelerating new starts, prescriber growth, and hospital adoption. Management also described a large runway from label improvements and new formats, including a mid-2027 simplified IV regimen and a 2028 subcutaneous launch, while citing long-term data that they believe support differentiation versus other anti-CD20 options. The company is also profitable and has meaningful cash, giving it room to invest and return capital.
The biggest risks are execution and timing: the simplified IV regimen is not expected to help immediately and the subcutaneous program still depends on Phase III data, regulatory review, and CMC readiness. Gross-to-net pressure, payer mix, and government discounts remain ongoing concerns, even if management believes they can offset them. Competitive pressure is also not gone, especially if rivals push convenience or pricing arguments, and management acknowledged that 340B policy changes could affect part of the business even if the expected impact is small.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 88.3%
- Shares Outstanding
- 151.15M
- Float Shares
- 133.49M
of shares held by institutions
465 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TGTX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Sell | Sep 8, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.63M | ▲ 584.89K |
| Vanguard Group Inc | 15.84M | ▲ 319.70K |
| State Street Corp | 8.49M | ▲ 702.40K |
| Vanguard Portfolio Management LLC | 7.88M | ▼ 82.72K |
| Vanguard Capital Management LLC | 6.26M | ▲ 107.02K |
| Geode Capital Management, LLC | 3.70M | ▲ 61.46K |
| D. E. Shaw & Co., Inc. | 3.40M | ▲ 2.81M |
| Soleus Capital Management, L.P. | 2.93M | ▼ 1.10M |
| Price T Rowe Associates Inc | 2.77M | ▲ 2.13M |
| Congress Asset Management Co | 2.61M | ▲ 6.39K |
| Two Sigma Investments, LP | 2.47M | ▲ 926.66K |
| Barclays PLC | 2.42M | ▲ 1.47M |
Held by 447 ETFs
Biggest fund positions in TGTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | Charney Laurence N | sell | 5,000 |
| Aug 6, 26 | Charney Laurence N | other | 5,100 |
| Aug 7, 26 | Charney Laurence N | other | 500 |
| Aug 7, 26 | Charney Laurence N | other | 450 |
| Jun 11, 26 | Lonial Sagar | other | 8,325 |
| Jun 11, 26 | HUME DANIEL | other | 8,325 |
| Jun 11, 26 | Hoberman Kenneth | other | 8,325 |
| Jun 11, 26 | Echelard Yann | other | 8,325 |
| Jun 11, 26 | Charney Laurence N | other | 8,325 |
| Jan 28, 26 | Charney Laurence N | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TGTX coverage
Recent articles, reports, and earnings notes.
No research on TGTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TGTX report →